Weekly Analysts’ Ratings Changes for Depomed (DEPO)

Several analysts have recently updated their ratings and price targets for Depomed (NASDAQ: DEPO):

  • 3/15/2017 – Depomed was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $15.44 price target on the stock.
  • 3/2/2017 – Depomed was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $15.44 price target on the stock.
  • 3/1/2017 – Depomed was given a new $19.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 2/27/2017 – Depomed had its “buy” rating reaffirmed by analysts at Janney Montgomery Scott.
  • 2/23/2017 – Depomed had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $22.00 price target on the stock.
  • 2/20/2017 – Depomed was downgraded by analysts at Mizuho from a “buy” rating to a “neutral” rating.
  • 2/18/2017 – Depomed was given a new $24.00 price target on by analysts at Roth Capital. They now have a “buy” rating on the stock.
  • 2/14/2017 – Depomed was downgraded by analysts at Mizuho from a “buy” rating to a “neutral” rating. They now have a $17.00 price target on the stock, down previously from $24.00.

Shares of Depomed Inc (NASDAQ:DEPO) traded down 0.222% on Monday, hitting $15.745. 899,140 shares of the company were exchanged. The company has a 50-day moving average price of $16.61 and a 200 day moving average price of $20.04. Depomed Inc has a 52-week low of $12.25 and a 52-week high of $27.02. The firm’s market cap is $977.75 million.

Depomed (NASDAQ:DEPO) last released its earnings results on Tuesday, February 21st. The specialty pharmaceutical company reported $0.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.36 by $0.13. The company had revenue of $123.90 million for the quarter, compared to analyst estimates of $123 million. Depomed had a negative net margin of 16.93% and a negative return on equity of 7.49%. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.16 EPS. Analysts predict that Depomed Inc will post $1.16 EPS for the current fiscal year.

5 Day Chart for NASDAQ:DEPO

Receive News & Ratings for Depomed Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.